Relief And Rebuke For Biocon In Herceptin Biosimilars Case
This article was originally published in Scrip
Executive Summary
An Indian court did not hold back the launch of Biocon's biosimilar version of Roche's Herceptin (trastuzumab) for two additional indications - early breast cancer and metastatic gastric cancer - but had some tough words against the Bengaluru-based firm on its apparent "conduct" in obtaining regulatory approval of the carton, labels and the package insert.